174 related articles for article (PubMed ID: 16162008)
1. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
[TBL] [Abstract][Full Text] [Related]
2. 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Diaz G; Glaser KB; Guo J; Harris CM; Li J; Marcotte PA; Moskey MD; Oie T; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR
J Med Chem; 2008 Mar; 51(5):1231-41. PubMed ID: 18260617
[TBL] [Abstract][Full Text] [Related]
3. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
6. Thienopyridine urea inhibitors of KDR kinase.
Heyman HR; Frey RR; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Soni NB; Marcotte PA; Pease LJ; Glaser KB; Yates M; Bouska JJ; Albert DH; Black-Schaefer CL; Dandliker PJ; Stewart KD; Rafferty P; Davidsen SK; Michaelides MR; Curtin ML
Bioorg Med Chem Lett; 2007 Mar; 17(5):1246-9. PubMed ID: 17188869
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
Sammond DM; Nailor KE; Veal JM; Nolte RT; Wang L; Knick VB; Rudolph SK; Truesdale AT; Nartey EN; Stafford JA; Kumar R; Cheung M
Bioorg Med Chem Lett; 2005 Aug; 15(15):3519-23. PubMed ID: 15990302
[TBL] [Abstract][Full Text] [Related]
8. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Garofalo A; Farce A; Ravez S; Lemoine A; Six P; Chavatte P; Goossens L; Depreux P
J Med Chem; 2012 Feb; 55(3):1189-204. PubMed ID: 22229669
[TBL] [Abstract][Full Text] [Related]
10. Isoindolinone ureas: a novel class of KDR kinase inhibitors.
Curtin ML; Frey RR; Heyman HR; Sarris KA; Steinman DH; Holmes JH; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Pease LJ; Glaser KB; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2004 Sep; 14(17):4505-9. PubMed ID: 15357981
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation.
Zhou H; Wang DA; Baldini L; Ennis E; Jain R; Carie A; Sebti SM; Hamilton AD
Org Biomol Chem; 2006 Jun; 4(12):2376-86. PubMed ID: 16763682
[TBL] [Abstract][Full Text] [Related]
12. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
[TBL] [Abstract][Full Text] [Related]
13. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
14. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
16. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
17. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
[TBL] [Abstract][Full Text] [Related]
18. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
20. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
Miyazaki Y; Matsunaga S; Tang J; Maeda Y; Nakano M; Philippe RJ; Shibahara M; Liu W; Sato H; Wang L; Nolte RT
Bioorg Med Chem Lett; 2005 May; 15(9):2203-7. PubMed ID: 15837294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
